© 2023 MergersCorp M&A International. is a global brand operating through a number of professional firms and constituent entities located throughout the world to provide M&A Advisory and other client related professional services. The Member Firms are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit us on our website https://mergerscorp.com/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws.
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by MergersUS Inc. or any other third party regardless of whether such security, product or service is referenced in this website. Furthermore, nothing in this website is intended to provide tax, legal, or investment advice and nothing in this website should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction.
This website is operated by MergersUS Inc.a US Corporation with registered office at 40th Wall Street, Suite #2725, New York, New York 10005, United States of America.
This company has been in the Colombian market for 19 years, it owns the approved INVIMA registrations.
There is a serious conversations to expand market to Guatemala and 5 more countries in Central America with one big distributor. There are 289 affiliated pharmacies in all main cities of Colombia and in many secondary cities. The CRM is very well organized, with 1397 members between doctors, pharmacies and the institutional market. There are 289 affiliated pharmacies in all main cities of Colombia and in many secondary cities.
The company buys the API, the excipients, the packaging and the products, and everything is made by outsourcing in specialized plants in Colombia that are approved by the INVIMA.
Currently, there are 32 products registered and approved by the INVIMA and the Superintendence of Industry and Commerce. Two new products are about to be approved by the INVIMA.
An approval by the INVIMA in Colombia takes an average of 2 years and USD $30.000 of investment to achieve.
This business has 5 nutritional products, of which we own the brand, but not the registry.
o Antibiotics
o Analgesics
o Anti-inflammatory
o Antihistamines
o Cardiovascular
o Nutritional
o Gastroenterology
o Lipid lowering drugs
o Pediatric Products: Antibiotics and Nutritional.
© 2023 MergersCorp M&A International is a global brand operating through a number of professional firms and constituent entities located throughout the world to provide M&A Advisory and other client related professional services. The Member Firms are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit us on our website https://mergerscorp.com/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws.
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by MergersUS Inc. or any other third party regardless of whether such security, product or service is referenced in this website. Furthermore, nothing in this website is intended to provide tax, legal, or investment advice and nothing in this website should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction.
This website is operated by MergersUS Inc.a US Corporation with registered office at 40th Wall Street, Suite #2725, New York, New York 10005, United States of America.
This website is operated by MergersUS Inc a US Corporation with registered office at
Error: Contact form not found.
Error: Contact form not found.
Error: Contact form not found.
Error: Contact form not found.
Description
This company has been in the Colombian market for 19 years, it owns the approved INVIMA registrations.
There is a serious conversations to expand market to Guatemala and 5 more countries in Central America with one big distributor. There are 289 affiliated pharmacies in all main cities of Colombia and in many secondary cities. The CRM is very well organized, with 1397 members between doctors, pharmacies and the institutional market. There are 289 affiliated pharmacies in all main cities of Colombia and in many secondary cities.
Commercial Market
The company buys the API, the excipients, the packaging and the products, and everything is made by outsourcing in specialized plants in Colombia that are approved by the INVIMA.
Currently, there are 32 products registered and approved by the INVIMA and the Superintendence of Industry and Commerce. Two new products are about to be approved by the INVIMA.
An approval by the INVIMA in Colombia takes an average of 2 years and USD $30.000 of investment to achieve.
This business has 5 nutritional products, of which we own the brand, but not the registry.
Products
o Antibiotics
o Analgesics
o Anti-inflammatory
o Antihistamines
o Cardiovascular
o Nutritional
o Gastroenterology
o Lipid lowering drugs
o Pediatric Products: Antibiotics and Nutritional.
Basic Details
Target Price:
$11,500,000
Gross Revenue
$2,000,000
EBITDA
$450,000
Established
2002
Business ID:
L#20210109
Country
Colombia
City:
Bogota
Detail
Similar Businesses
Published on June 14, 2021 at 1:08 pm. Updated on December 2, 2023 at 2:02 pm
30 Year Old Manufacturer and Exporter of Jewelry to USA/Europe
$60,000,000
Manufacturing
Swiss Company offering versatile 3D technology
TBD
Manufacturing
Stock Market Broker House with 35,000+ clients
$5,000,000
Manufacturing
Portfolio of 2x Swiss Businesses active in Metal Sheet Processing Business
TBA
Manufacturing
Waste Collection Recycling and Recovery Business
€1,600,000
Manufacturing
15-Year-Old Large Confectionery Production Business
$2,600,000
Manufacturing
PREVIOUS PROPERTY
B2B / B2C Wholesale Online Marketplace with 3,000,000 Customers
NEXT PROPERTY
1M Customers Digital Financial Transaction Platform